ACOT7, CPTAC-303 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

10 20 30 40 50
MKLLARALRL CEFGRQASSR RLVAGQGCVG PRRGCCAPVQ VVGPRADLPP
60 70 80 90 100
CGACITGRIM RPDDANVAGN VHGGTILKMI EEAGAIISTR HCNSQNGERC
110 120 130 140 150
VAALARVERT DFLSPMCIGE VAHVSAEITY TSKHSVEVQV NVMSENILTG
160 170 180 190 200
AKKLTNKATL WYVPLSLKNV DKVLEVPPVV YSRQEQEEEG RKRYEAQKLE
210 220 230 240 250
RMETKWRNGD IVQPVLNPEP NTVSYSQSSL IHLVGPSDCT LHGFVHGGVT
260 270 280 290 300
MKLMDEVAGI VAARHCKTNI VTASVDAINF HDKIRKGCVI TISGRMTFTS
310 320 330 340 350
NKSMEIEVLV DADPVVDSSQ KRYRAASAFF TYVSLSQEGR SLPVPQLVPE
360 370 380
TEDEKKRFEE GKGRYLQMKA KRQGHAEPQP

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader


Assay Details for CPTAC-304 Collapse assay details

Data source: Panorama

Official Gene Symbol

ACOT7

Peptide Sequence

AASAFFTYVSLSQEGR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

325

Peptide End

340

CPTAC ID

CPTAC-304

Peptide Molecular Mass

1,732.8421

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Broad Institute and FHCRC

Submitting Lab PI

Steve Carr


Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y10 (1+) | 7.7 | 7.7 | 6.9 | 12.6 | 11.9 | 16.9 | 14.8 | 14.2 | 18.3 | 25 | 15 | 15 | | y9 (1+) | 13 | 10 | 12.7 | 20.2 | 13.3 | 21.1 | 24 | 16.6 | 24.6 | 25 | 15 | 15 | | y8 (1+) | 10.2 | 10.6 | 8 | 17 | 11.2 | 19.6 | 19.8 | 15.4 | 21.2 | 25 | 15 | 15 | | sum | 8.8 | 6.6 | 6.5 | 14.5 | 10.5 | 16.9 | 17 | 12.4 | 18.1 | 25 | 15 | 15 |



Additional Resources and Comments


Assay Details for CPTAC-303 Collapse assay details

Data source: Panorama

Official Gene Symbol

ACOT7

Peptide Sequence

VLEVPPVVYSR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

173

Peptide End

183

CPTAC ID

CPTAC-303

Peptide Molecular Mass

1,256.7129

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Broad Institute and FHCRC

Submitting Lab PI

Steve Carr


Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Response curves acquired at Broad Institute. Repeatability data acquired at Fred Hutchinson Cancer Research Center.


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C and 15N R

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y9 (1+) | 21.5 | 8 | 7.3 | 18.8 | 8.7 | 10.5 | 28.6 | 11.8 | 12.8 | 15 | 25 | 15 | | y7 (1+) | 10.3 | 5.5 | 2.8 | 11.7 | 8.6 | 4.8 | 15.6 | 10.2 | 5.6 | 15 | 25 | 15 | | y6 (1+) | 52.5 | 12.4 | 11.3 | 65.6 | 12.9 | 16.5 | 84 | 17.9 | 20 | 15 | 25 | 15 | | sum | 11.6 | 5.4 | 2.9 | 15.4 | 8.2 | 4.3 | 19.3 | 9.8 | 5.2 | 15 | 25 | 15 |



Additional Resources and Comments